Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML-II

Children's Oncology Group0 个研究点目标入组 150 人2010年5月

适应症Leukemia

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: Leukemia
发起方: Children's Oncology Group
入组人数: 150
主要终点: Correlation of constitutive pStat3 with inducible pStat3
状态: 已完成
最后更新: 9年前

概览研究者入排标准结局指标相似试验

概览

简要总结

RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is studying prognostic biomarkers in cell samples from young patients with acute myeloid leukemia.

详细描述

OBJECTIVES: Primary * To determine the percentage of primary acute myeloid leukemia (AML) samples with increased Stat3 signaling pathway activity. * To evaluate the presence of constitutive Stat3 activation and the sensitivity of Stat3 activation to low- and high-doses of cytokines. * To evaluate the expression levels of Stat3 protein and the upstream and downstream regulators of Stat3 activation. Secondary * To classify samples according to a Stat3 activation pattern and correlate this result with event-free survival (EFS) and overall survival (OS). OUTLINE: Cryopreserved AML specimens are analyzed for pStat3 and pStat5 levels, response to cytokine levels, and expression level of proteins known to influence stat activity by flow cytometry and western blot assays. Results are also compared with prognostic variables determined in CCG-291 study, including age, race, WBC, and cytogenetic risks.

注册库

clinicaltrials.gov

开始日期

2010年5月

结束日期

2016年5月

最后更新

9年前

研究类型

Observational

性别

All